Hansa Biopharma plans to restructure the organisation to optimise resource allocation and improve op...
Redeye comments on Lipigon’s first quarter report 2025.
Redeye comments on Active Biotech’s multiple myeloma results, which were in line with previous reado...
Redeye provides its preview of Integrum’s Q4 2024 report, due on Tuesday, June 3.
Redeye provides an update following Jumpgate’s Q1 2025 report, where we observed a top line largely ...
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det första...
Seasonally weak quarter, but 2025 guidance firm '25e-'27e adj.
With its third attempt to scale offline payments in India, Crunchfish hopes that its new Offline Ter...
Ahead of Solwers' Q1 2025 report, we cut our EBIT estimates by 9-11% for 2025-27 as we expect a some...
Redeye comments on Friday evening’s news from Dala Energi’s AGM, where the voluntary share redemptio...
6% organic sales growth y-o-y SaaS momentum drives gross margin uplift.
Redeye comments on Faron’s recent publication in a scientific journal, which provides valuable mecha...
Adj. EBITDA 35% above, but boosted by one-offs in Senior Soft watch sales, but volumes will shift to...
Redeye updates on GiG after Q1-results which were in line with our expectations and we leave our est...
Redeye’s forecasts and valuation remain unchanged following today’s announced outcome of the TO3 war...
